A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Sapropterin (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 28 Jul 2009 Actual end date changed from Feb 2007 to Dec 2008 as reported by ClinicalTrials.gov.
- 21 Jan 2008 New trial record.
- 20 Feb 2007 Results reported; primary endpoint 'Systolic blood pressure' has not been met as reported by BioMarin Pharmaceutical.